Germany – Pharmaceutical products – Conclusion of a non-exclusive discount agreement according to § 130a Paragraph 8 SGB V for biosimilar active ingredients
Germany | Pharmaceuticals | Goods | Active
Opportunity Overview
§ 130a Paragraph 8 SGB V enables health insurance funds (KK) and pharmaceutical companies to conclude framework discount agreements for medicinal products to be dispensed at the expense of statutory health insurance funds. The the contracting authority acts for its shareholder and customer health insurance funds as a company for economic efficiency and quality at health insurance funds in accordance with § 130a Paragraph 8 Sentence 5 SGBV. With regard to the relevant legal regulations for awarding public contracts, the contracting authority conducts a regular process of active ingredient-related, formal award procedures in accordance with the regulations of the 4th part of the GWB. The contract start date is 01.10.2026.
Country
Germany
Procurement type
Goods
Procedure
open
Products, Services or Capabilities Requested
Goods required: Germany – Pharmaceutical products – Conclusion of a non-exclusive discount agreement according to § 130a Paragraph 8 SGB V for biosimilar active ingredients
Supplier Requirements
Original notice language: German
Selection criteria: .
Shown only where stated in, or derived directly from, the source notice. Always confirm requirements in the official notice.
Important Dates
Published
August 2, 2026
Submission deadline
August 10, 2027
Contract start
October 1, 2026
Contract end
September 30, 2028
Access the Full Opportunity
This opportunity is open for U.S. companies to evaluate.
Create your free exporter profile or sign in to your existing account. Full procurement details are available with Trade Intelligence.
The subject of this publication is the conclusion of non-exclusive rebate agreements pursuant to Section 130a (8) SGB V for drugs containing the active ingredient Epinephrine (WHO ATC code: C01CA24) in the dosage form of pre-filled syringe/pre-filled pen - exclusive 500 microgram
